Clinical trial · Observational
Role of Perfusion CT in Pancreatic Cancer
Evaluation of Diagnostic Efficacy of Perfusion CT Using Wide Detector for Staging and Response Prediction After Chemotherapy in Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is 1. to determine whether the perfusion parameters in the normal pancreas and the pancreas cancer (adenocarcinoma or neuroendocrine tumor) are different on perfusion CT 2. to determine whether initial perfusion parameters as well as perfusion parameter change in pancreas adenocarcinoma before and after chemotherapy are different between chemotherapy response group (CR, PR according to RECIST 1.1) and non response group (SD, PD according to RECIST 1.1).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma, Pancreas | Pancreatic Adenocarcinoma | ALIAS | 0.90 |
| Neuroendocrine Carcinoma of Pancreas | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CT | Procedure | — | UNRESOLVED |
| iopromide | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Resectable pancreas cancer
- description
- patients with resectable pancreas adenocarcinoma or neuroendocrine tumor underwent perfusion CT after intravenous iopromide administration
- interventionNames
- Drug: iopromide
- Procedure: CT
- label
- Locally advanced Pancreas cancer
- description
- Patients with locally advanced pancreas cancer underwent perfusion CT after intravenous iopromide administration before and after chemotherapy.
- interventionNames
- Drug: iopromide
- Procedure: CT
Primary outcomes (1)
- measure
- Evaluation of the correlation between the initial perfusion parameters of the tumor and response of the chemotherapy
- timeFrame
- after 6 cycles of the planned chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients who are older than eighteen years * patients in whom operation and preoperative computed tomography are scheduled for resectable pancreas adenocarcinoma or pancreas neuroendocrine tumor * patients in whom chemotherapy is scheduled for histologically confirmed pancreas adenocarcinoma * patients in whom chemotherapy is planned for highly suspicious pancreas adenocarcinoma on imaging workup * patients who agree with the study and whose informed consent is obtained. Exclusion Criteria: * patients who are younger than eighteen years old * patients in whom previously radiation therapy was performed and the RTx field includes pancreas * patients with recurred pancreas adenocarcinoma * patient who are pregnant or nursing patients * patients with renal failure (GFR\<30mL/min) * patients with history of malignancy, except malignancy is in complete remission after operation or iodine therapy for at least five years) * patients with hypersensitivity for iodine or contrast media or other causes of contraindication of contrast-media enhanced CT scan * Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with the completion of the study.
References
Publications (0)
Data not yet available